Findings

What do systematic reviews say?

Ignored "OS": search terms need at least 3 characters.

7 questions · 7 findings · 1 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 6 · 85.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Nivolumab vs no other intervention

OS · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 260 participants
Very low

Nivolumab vs no other intervention

QoL · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Nivolumab vs no other intervention

PFS · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 283 participants
Very low

Nivolumab vs no other intervention

Response rate · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 283 participants
Very low

Nivolumab vs no other intervention

Treatment‐related mortality · adults with Hodgkin's lymphoma

The review found no eligible studies for this question.

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nivolumab vs no other intervention

Grades 3 and 4 adverse events · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 283 participants
Very low

Nivolumab vs no other intervention

SAEs · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 243 participants
Very low